Lupin Spins Out 2 Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy
Lupin has spun off two oncology programs into Kaveri Therapeutics, retaining a significant equity stake while providing seed funding and exclusive program rights.
Clinical-stage Oncology Company, | 22/07/2026 | By News Bureau
New patient-derived xenograft study demonstrates strong synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer, paving the way for expanded clinical evaluation in Phase 1/2a trials.
Clinical-stage Oncology Company | 09/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy